AbbVie disclosed on 12 January the FDA had approved Duopa, an enteral suspension formulation of carbidopa and levodopa, as a treatment for motor fluctuations in patients with advanced Parkinson's disease.
AbbVie's Parkinson's drug Duopa OK'd in US
AbbVie disclosed on 12 January the FDA had approved Duopa, an enteral suspension formulation of carbidopa and levodopa, as a treatment for motor fluctuations in patients with advanced Parkinson's disease.
More from Alimentary/Metabolic
More from Therapy Areas
• By
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.